BIOCYTOGEN PHARMA. H YC1 Cash Flow Reinvestment Rate

Latest as of December 2025: 0.24x

BIOCYTOGEN PHARMA. H YC1 cash flow reinvestment rate. BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow Reinvestment Rate of 0.24x as of December 2025, reinvesting €90.49 Million (capex €87.82 Million plus investments €2.67 Million) from operating cash flow of €370.25 Million. Explore debt repayment capacity of BIOCYTOGEN PHARMA. H YC1 to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.24x

(Capex + Investments) / Operating CF

Total Reinvested

€90.49 Million

Capex + Investments

Operating Cash Flow

€370.25 Million

EUR

Capital Expenditures

€87.82 Million

EUR

Cash Flow Reinvestment Rate of BIOCYTOGEN PHARMA. H YC1 (2024–2025)

Cash flow reinvestment rate of BIOCYTOGEN PHARMA. H YC1 from 2024 to 2025. Historical reinvestment intensity for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. Explore BIOCYTOGEN PHARMA. H YC1 (I54) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

BIOCYTOGEN PHARMA. H YC1 Cash Flow Reinvestment Rate by Year (2024–2025)

BIOCYTOGEN PHARMA. H YC1 cash flow reinvestment rate by year from 2024 to 2025. Year-by-year capital reinvestment analysis for BIOCYTOGEN PHARMA. H YC1. For the full cash flow conversion analysis, see BIOCYTOGEN PHARMA. H YC1 (I54) cash conversion ratio.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2025	0.24x	€90.49 Million	€370.25 Million	€87.82 Million	▲ +35.1%
2024	0.18x	€38.22 Million	€211.25 Million	€37.13 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow